BG102288A - Заместени бензиламинопиперидини - Google Patents

Заместени бензиламинопиперидини

Info

Publication number
BG102288A
BG102288A BG102288A BG10228898A BG102288A BG 102288 A BG102288 A BG 102288A BG 102288 A BG102288 A BG 102288A BG 10228898 A BG10228898 A BG 10228898A BG 102288 A BG102288 A BG 102288A
Authority
BG
Bulgaria
Prior art keywords
halogen
alkoxy
alkyl
optionally substituted
substituted
Prior art date
Application number
BG102288A
Other languages
English (en)
Other versions
BG64126B1 (bg
Inventor
Kunio Satake
Yuji Shishido
Hiroaki Wakabayashi
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG102288A publication Critical patent/BG102288A/bg
Publication of BG64126B1 publication Critical patent/BG64126B1/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Бензиламинопиперидините намират приложение за лечение на стомашно-чревни смущения, смущения в централната нервна система, възпалителни заболявания, повръщане, незадържане на урината, болка, мигрена, слънчеви изгаряния, заболявания, причинени от Heliсobacter pylori и смущения и неблагоприятни състояния или ангиогенеза. Те имат формула, в която R е халоген-С1-С8-алкил, халоген-С2-С8-алкенил, халоген-С2-С8-алкинил или халоген-С1-С8-алкил, заместенис хидрокси или С1-С8 алкокси, R1 е водород, халоген или С1-С6 алкокси, или R и R1 заедно с двата въглеродни атома, които разделят бензеновия пръстен и заместителите R и R1, образуват кондензиран С4-С6 циклоалкил, в който един въглероден атом в даденслучай е заместен с кислород и в който един или два от въглеродните атоми в даден случай са заместени с до пет заместителя, избрани от халоген, С1-С6алкил и халоген-С1-С6-алкил, Х е С1-С6 алкокси, халоген-С1-С6-алкокси, фенокси или халоген и Ar е фенил, в даден случай заместен с халоген.Изобретението се отнася и до техни фармацевтично приемливи соли.
BG102288A 1995-08-24 1998-02-27 Заместени бензиламинопиперидини BG64126B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9500683 1995-08-24
PCT/IB1996/000572 WO1997008144A1 (en) 1995-08-24 1996-06-10 Substituted benzylaminopiperidine compounds

Publications (2)

Publication Number Publication Date
BG102288A true BG102288A (bg) 1998-09-30
BG64126B1 BG64126B1 (bg) 2004-01-30

Family

ID=11004362

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102288A BG64126B1 (bg) 1995-08-24 1998-02-27 Заместени бензиламинопиперидини

Country Status (42)

Country Link
US (1) US6506775B1 (bg)
EP (2) EP0861235B1 (bg)
JP (1) JP3084069B2 (bg)
KR (1) KR100288673B1 (bg)
CN (1) CN1153764C (bg)
AP (1) AP643A (bg)
AR (1) AR006305A1 (bg)
AT (2) ATE208377T1 (bg)
AU (1) AU702698B2 (bg)
BG (1) BG64126B1 (bg)
BR (1) BR9609989A (bg)
CA (1) CA2227814C (bg)
CO (1) CO4480738A1 (bg)
CZ (1) CZ297543B6 (bg)
DE (2) DE69616817T2 (bg)
DK (2) DK1114817T3 (bg)
DZ (1) DZ2086A1 (bg)
ES (2) ES2211684T3 (bg)
HK (1) HK1014935A1 (bg)
HR (1) HRP960386B1 (bg)
HU (1) HU225480B1 (bg)
IL (1) IL119078A (bg)
IS (1) IS1947B (bg)
MA (1) MA23961A1 (bg)
MX (1) MX9801467A (bg)
MY (1) MY114800A (bg)
NO (1) NO310720B1 (bg)
NZ (1) NZ308207A (bg)
OA (1) OA10666A (bg)
PE (2) PE1398A1 (bg)
PL (1) PL186773B1 (bg)
PT (2) PT1114817E (bg)
RO (1) RO119299B1 (bg)
RU (1) RU2152930C2 (bg)
SI (2) SI1114817T1 (bg)
SK (1) SK282925B6 (bg)
TN (1) TNSN96107A1 (bg)
TR (1) TR199800300T1 (bg)
TW (1) TW340842B (bg)
UA (1) UA48981C2 (bg)
WO (1) WO1997008144A1 (bg)
YU (1) YU49122B (bg)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
AU3572800A (en) * 1999-05-06 2000-11-21 Pfizer Products Inc. Substituted benzolactam compounds
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
TR200103332T2 (tr) * 1999-05-21 2002-04-22 Pfizer Products Inc. 1-Triflorometil-4-hidroksi-7-piperidinil-aminometilkroman türevleri.
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
BRPI0409211A (pt) 2003-04-18 2006-03-28 Lilly Co Eli composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
BRPI0511183A (pt) * 2004-05-21 2007-12-04 Pfizer Prod Inc metabólitos de (+)-(2s, 3s)-3-(2-metóxi-5-trifluorometoxibenzilamino)-2-fenil- piperidina
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
SI2805945T1 (sl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2717509A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
EP2264029A4 (en) 2008-03-31 2011-08-24 Kowa Co 1,3-dihydroisobenzofuran DERIVATIVE
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
CA2760837C (en) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
ES2651347T3 (es) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785A4 (en) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
AU647592B2 (en) * 1991-03-26 1994-03-24 Pfizer Inc. Stereoselective preparation of substituted piperidines
CZ290475B6 (cs) * 1991-06-20 2002-07-17 Pfizer Inc. Fluoralkoxybenzylaminové deriváty heterocyklů obsahujících dusík, způsob jejich přípravy, meziprodukty tohoto postupu a pouľití těchto derivátů
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
EP0780375B1 (en) * 1995-12-21 2002-09-11 Pfizer Inc. 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
WO1997008144A1 (en) 1997-03-06
JP3084069B2 (ja) 2000-09-04
UA48981C2 (uk) 2002-09-16
PE20010700A1 (es) 2001-07-09
MX9801467A (es) 1998-05-31
OA10666A (en) 2002-11-25
MY114800A (en) 2003-01-31
SI0861235T1 (en) 2002-04-30
NO310720B1 (no) 2001-08-20
IL119078A0 (en) 1996-11-14
AR006305A1 (es) 1999-08-25
CZ52198A3 (cs) 1999-01-13
KR19990044077A (ko) 1999-06-25
AP643A (en) 1998-04-24
PE1398A1 (es) 1998-02-27
ATE208377T1 (de) 2001-11-15
SK282925B6 (sk) 2003-01-09
IL119078A (en) 2003-11-23
TW340842B (en) 1998-09-21
AU702698B2 (en) 1999-03-04
NO980751D0 (no) 1998-02-23
NO980751L (no) 1998-02-23
EP0861235B1 (en) 2001-11-07
HU225480B1 (en) 2006-12-28
ES2211684T3 (es) 2004-07-16
DE69631390T2 (de) 2004-11-25
HRP960386A2 (en) 1998-04-30
CO4480738A1 (es) 1997-07-09
EP1114817B1 (en) 2004-01-21
YU49122B (sh) 2004-03-12
DE69631390D1 (de) 2004-02-26
TR199800300T1 (xx) 1998-06-22
IS1947B (is) 2004-10-13
HK1014935A1 (en) 1999-10-08
SI1114817T1 (en) 2004-06-30
HRP960386B1 (en) 2002-04-30
PL325332A1 (en) 1998-07-20
ES2163017T3 (es) 2002-01-16
PT1114817E (pt) 2004-05-31
CN1193961A (zh) 1998-09-23
RO119299B1 (ro) 2004-07-30
AU5776996A (en) 1997-03-19
SK20798A3 (en) 1999-03-12
YU47896A (sh) 1998-12-23
CZ297543B6 (cs) 2007-02-07
NZ308207A (en) 1998-07-28
DE69616817D1 (de) 2001-12-13
HUP9901159A2 (hu) 1999-07-28
CA2227814C (en) 2002-12-31
EP0861235A1 (en) 1998-09-02
EP1114817A1 (en) 2001-07-11
DK0861235T3 (da) 2001-12-27
HUP9901159A3 (en) 2000-05-29
DE69616817T2 (de) 2002-04-04
IS4644A (is) 1997-12-30
TNSN96107A1 (fr) 2005-03-15
CA2227814A1 (en) 1997-03-06
PT861235E (pt) 2002-03-28
JPH10510554A (ja) 1998-10-13
DZ2086A1 (fr) 2002-07-22
US6506775B1 (en) 2003-01-14
PL186773B1 (pl) 2004-02-27
KR100288673B1 (ko) 2001-05-02
BR9609989A (pt) 1999-07-06
CN1153764C (zh) 2004-06-16
MA23961A1 (fr) 1997-04-01
DK1114817T3 (da) 2004-04-26
RU2152930C2 (ru) 2000-07-20
AP9600850A0 (en) 1996-10-31
ATE258166T1 (de) 2004-02-15
BG64126B1 (bg) 2004-01-30

Similar Documents

Publication Publication Date Title
BG102288A (bg) Заместени бензиламинопиперидини
ATE239477T1 (de) Chinolone und deren therapeutische verwendung
TR199901276T2 (xx) Farnezil protein transferaz inhibisyonu i�in yararl� bile�ikler.
PT663912E (pt) Compostos de eter heterociclico que aumentam a funcao cognitiva
IL107292A0 (en) Substituted benzylaminoquinuclidines
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
AU7698596A (en) Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives
IL108769A0 (en) Spirocyclic piperidine derivatives
ES8106723A1 (es) Un metodo para la preparacion de derivados de ftalimidina
CA2217771A1 (en) O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same
ES8609216A1 (es) Un procedimiento para la preparacion de derivados de aminofenol.
MX9606300A (es) Arilalquiltioalquiltiopiridinas substituidas para combatir bacterias helicobactas.
DE3072187D1 (de) Mittel zur regulierung des pflanzenwachstums, deren herstellung und deren verwendung.
NO991235D0 (no) Forbindelser anvendelige for inhibering av farnesylproteintransferase
ID22156A (id) Turunan substitusi benzosikloheptapiridina yang berguna untuk menghambat fernesil protein transferase
ATE277913T1 (de) Bisarylderivate mit fsh rezeptor modulierender aktivität
DK156571C (da) 1,3-dioxan-5-yl-alkyltriazoler, middel til regulering af plantevaekst og fremgangsmaade til regulering af plantevaekst
BG102618A (bg) Производни на 5н,1он-имидазо(1,2-а)инден(1,2-е)пиразин -4-он, получаването им техни междинни продукти и лекарства, които ги съдържат
AU2406700A (en) 3,4-dihydro-2h-benzo(1,4)oxazinyl-methyl(3-(1h-indol-3-yl)-a kyl)-amines
MA20461A1 (fr) Procede de preparation de nouveaux derives de l'isoxazoloquinoleine
DK1137660T3 (da) 22S-hydroxycholesta-8,14-dienderivater med meioseregulerende aktivitet
ES8307234A1 (es) "procedimiento para la preparacion de derivados de 1,2,3-tiadiazol-5-il-urea".
TR199901273T2 (xx) Farnezil protein transferaz inhibisyonu i�in yararl� bile�ikler.
DK0746556T3 (da) Tricycliske forbindelser med affinitet for 5-HT1A-receptoren